Lucid Diagnostics’ (LUCD) “Buy” Rating Reaffirmed at BTIG Research

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “buy” rating reiterated by stock analysts at BTIG Research in a research note issued on Friday,Benzinga reports. They presently have a $2.50 price objective on the stock. BTIG Research’s price target would indicate a potential upside of 145.10% from the stock’s current price.

Several other equities research analysts also recently commented on the stock. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Ascendiant Capital Markets lifted their price objective on shares of Lucid Diagnostics from $8.25 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Wednesday, May 6th. Finally, Needham & Company LLC restated a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a report on Thursday, March 26th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $4.83.

Lucid Diagnostics Stock Performance

Shares of LUCD opened at $1.02 on Friday. The business’s 50-day moving average price is $1.21 and its 200 day moving average price is $1.19. The stock has a market capitalization of $199.16 million, a P/E ratio of -1.06 and a beta of 1.10. Lucid Diagnostics has a 1-year low of $0.95 and a 1-year high of $1.70.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.38 million. On average, research analysts predict that Lucid Diagnostics will post -0.22 earnings per share for the current year.

Institutional Trading of Lucid Diagnostics

Institutional investors have recently made changes to their positions in the stock. Centiva Capital LP acquired a new position in Lucid Diagnostics in the 3rd quarter valued at approximately $25,000. Sprott Inc. acquired a new stake in shares of Lucid Diagnostics during the 3rd quarter valued at $25,000. SG Americas Securities LLC acquired a new stake in shares of Lucid Diagnostics during the 3rd quarter valued at $26,000. Abel Hall LLC purchased a new position in shares of Lucid Diagnostics during the 4th quarter valued at $33,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Lucid Diagnostics by 71,026.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock valued at $38,000 after acquiring an additional 32,672 shares in the last quarter. 74.01% of the stock is currently owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.